This is a summary of the European public assessment report (EPAR) for Vemlidy. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Vemlidy. For practical information about using Vemlidy, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication Vemlidy is indicated for the treatment of chronic hepatitis B (CHB) in adults and paediatric patients 6 years of age and older weighing at least 25 kg (see section 5.1).
Therapeutic Area (MeSH)
ATC Code
J05AF13
ATC Item
tenofovir alafenamide
Pharmacotherapeutic Group
Antivirals for systemic use
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| tenofovir alafenamide fumarate | N/A | Tenofovir |
EMA Name
Vemlidy
Medicine Name
Vemlidy
Aliases
N/ANo risk management plan link.
